Efavirenz anchored HIV treatment across much of the world for many years and remains a well understood antiretroviral medicine. Its position has changed as newer options have become preferred, largely because of how it is tolerated. This guide explains what efavirenz is, where it is used today, and the effects and monitoring points a treating doctor keeps under review.
Efavirenz is often abbreviated to EFV and appears in the older combination abbreviated as TLE.
| Important note This article is general information about medicines used in HIV care. It does not include dosing instructions and is not a substitute for medical advice. All HIV medicines are prescription-only and are selected, started, and changed by a qualified doctor. |
Quick Summary / Key Takeaways
|
Efavirenz anchored HIV treatment across much of the world for many years and remains a well understood antiretroviral medicine. Its position has changed as newer options have become preferred, largely because of how it is tolerated. Efavirenz is often abbreviated to EFV.
Efavirenz belongs to the NNRTI class described in the guide to NNRTIs: efavirenz and nevirapine. It attaches to reverse transcriptase, the enzyme HIV uses to convert and copy its genetic material, and changes its shape so the enzyme can no longer function.
For people starting treatment now, current guidance points to regimens built around dolutegravir, as set out in first-line ART regimens explained.
Efavirenz is best known for effects involving the nervous system, which typically appear early and often lessen over the first weeks. Reported effects include:
| Consideration | What is generally observed |
|---|---|
| Timing of nervous system effects | Usually early, often lessening over the first weeks |
| Sleep and dreams | Vivid dreams and disturbed sleep are commonly reported |
| Mood | Changes in mood are monitored and should be reported |
| Skin | Rash is usually mild and early; persistent rash needs review |
| Liver measures | Reviewed as part of routine follow-up |
Efavirenz-based treatment was the WHO preferred first-line option until 2018. Guidance shifted towards dolutegravir because it is generally better tolerated and holds up more strongly against resistance. Efavirenz remains effective, and the change reflects the availability of options that suit more people.
| Myth | Fact |
|---|---|
| Efavirenz is no longer used anywhere. | It remains in use in defined situations decided by a doctor. |
| Nervous system effects last indefinitely. | They typically appear early and often lessen over the first weeks. |
| Mood changes should simply be tolerated. | Any change in mood should be reported to the treating doctor. |
| Efavirenz does not work well. | It is effective; newer options are generally better tolerated. |
| Timing of the dose makes no difference. | Treating doctors commonly advise on timing to help with early effects. |
| When to Consult a Doctor Medical advice is appropriate where nervous system effects continue beyond the early weeks, where any change in mood occurs, where a rash appears or persists, and before starting or changing treatment. A consultation can be arranged through an HIV doctor consultation. |
Efavirenz is an effective NNRTI that anchored HIV treatment internationally for many years. Its best known consideration is a group of nervous system effects that usually appear early and often lessen with time. Current guidance now prefers dolutegravir-based regimens, although efavirenz retains a defined place in care decided by the treating doctor.
For expert guidance, TAAL+ Healthcare offers HIV treatment & ART care and a confidential HIV doctor consultation.
Efavirenz is an NNRTI used as part of combination HIV treatment in established regimens, where an integrase inhibitor is not suitable, or in specific circumstances assessed by a doctor.
Efavirenz is best known for nervous system effects including dizziness, vivid dreams, disturbed sleep, and difficulty concentrating. Changes in mood and an early mild rash are also reported.
Nervous system effects typically appear early and often lessen over the first weeks. Where effects continue beyond that period, medical review is appropriate.
Vivid or unusual dreams and disturbed sleep are commonly reported, particularly in the early weeks. Doctors often advise on the time of day the medicine is taken.
It was preferred until 2018, when guidance moved towards dolutegravir. The change reflects better tolerability and a stronger barrier to resistance with the newer option.
Yes. Any change in mood should be reported to the treating doctor rather than waited out.
Yes. The move in guidance towards dolutegravir reflects tolerability and resistance considerations rather than a lack of effectiveness.
A regimen that is working well may be continued following medical review. Any decision about changing treatment is made by the treating doctor.
+91 98925 15959
Before You Go
The HIV Test Kit Is Still FREE
A private HIV self-test, delivered in plain packaging. Result in 20 minutes, at home. No cost, no clinic visit, and a TAAL+ doctor on call whichever way it goes.
Offer valid only in India till 30 September 2026. T&Cs apply.
